Ocular Therapeutix, Inc.
NASDAQ Global MarketRecent
price
P/E
ratio
div
yld
- -
ROIC.AI
Capital Structure
•
in mil. unless spec.Working Capital
•
in mil. unless spec.Growth Rates
•
in mil. unless spec.Quarterly Revenue
•
in mil. unless spec.Quarterly Earnings Per Share
•
in mil. unless spec.Quarterly Dividends Per Share
•
in mil. unless spec.- Similar Companies
- Business
- Ocular Therapeutix, Inc. (Nasdaq: OCUL) develops and commercializes innovative therapies for retinal diseases and other ophthalmic conditions using its proprietary ELUTYX bioresorbable hydrogel-based delivery platform. The company markets DEXTENZA, a sustained-release intracanalicular dexamethasone insert for the treatment of ocular inflammation and pain following ophthalmic surgery in adults and pediatric patients, and ocular itching associated with allergic conjunctivitis in adults and pediatric patients aged two years or older; its pipeline includes AXPAXLI (axitinib intravitreal hydrogel, also known as OTX-TKI), an investigational therapy in Phase 3 clinical trials for wet age-related macular degeneration (wet AMD), with planned expansion into non-proliferative diabetic retinopathy (NPDR) and diabetic macular edema (DME); PAXTRAVA (travoprost intracameral hydrogel), an investigational sustained-release implant for open-angle glaucoma or ocular hypertension; and other candidates leveraging ELUTYX technology for sustained delivery of anti-VEGF agents and tyrosine kinase inhibitors to address limitations of frequent eye-drop and intravitreal injection therapies. Founded in 2006 and headquartered in Bedford, Massachusetts, the company operates primarily in the United States with license and collaboration agreements, including with AffaMed Therapeutics Limited for the development and commercialization of DEXTENZA and PAXTRAVA in certain regions. In 2025, Ocular Therapeutix sharpened its strategic focus exclusively on retinal diseases, rebranding as a retina-centered biopharmaceutical company; raised approximately $475 million through an underwritten public offering of 37.9 million shares priced at $12.53 each in September to fund Phase 3 trials and open-label extension studies for AXPAXLI in wet AMD and NPDR, manufacturing scale-up, and potential commercialization; and reported third-quarter financial results highlighting total cash position of $344.8 million as of September 30, excluding additional offering proceeds.
Company News
Ocular Therapeutix™ Reports Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)
Ocular Therapeutix™ to Participate in October Scientific and Investor Conferences
Ocular Therapeutix Eyes Q4 FDA Filing for AXPAXLI After SOL-1 Success
Ocular Therapeutix™ Reports Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)
Ocular Therapeutix™ Announces Positive Pre-NDA Meeting with U.S. FDA for AXPAXLI™ in Wet AMD
Ocular Therapeutix™ to Participate in September and October Investor and Scientific Conferences
BlackRock Inc. Invests $190.28 Million in Ocular Therapeutix, Inc. $OCUL
Ocular Therapeutix, Inc. (OCUL) Discusses Regulatory Progress and NDA Filing Plans for AXPAXLI Transcript
Why Is Ocular Therapeutix Stock Gaining Monday?
Ocular Therapeutix™ Reports Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)
California State Teachers Retirement System Increases Stock Position in Ocular Therapeutix, Inc. $OCUL
Ocular Therapeutix™ Reports Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)
Ocular Therapeutix: AXPAXLI Can Turn Retina Capacity Into A Commercial Moat
Ocular Therapeutix (OCUL) Reports Q2 Loss, Beats Revenue Estimates
Ocular Therapeutix™ Reports Second Quarter 2026 Financial Results and Business Highlights
Ocular Therapeutix Eyes Q4 AXPAXLI NDA After FDA Alignment
Ocular Therapeutix™ Reports Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)
Ocular Therapeutix™ to Participate in July Scientific and Investor Conferences
Ocular Therapeutix™ to Participate in July Scientific and Investor Conferences
Ocular Therapeutix™ Reports Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)